Phase I Study of Panobinostat with ICE in Relapsed/Refractory Hodgkin Lymphoma
CME INFORMATION

OVERVIEW OF ACTIVITY

Each year, thousands of clinicians, basic scientists, and other industry professionals sojourn to major international oncology conferences, like the American Society of Hematology (ASH) annual meeting, to hone their skills, network with colleagues and learn about recent advances altering state-of-the-art management in hematologic oncology. As such, these events have become global stages where exciting science, cutting-edge concepts and practice-changing data emerge on a truly grand scale. This massive outpouring of information has enormous benefits for the hematologic oncology community, but the truth is it also creates a major challenge for practicing oncologists and hematologists.

Although original data are consistently being presented and published, the flood of information unveiled during a major academic conference is unprecedented and leaves in its wake an enormous volume of new knowledge that practicing oncologists must try to sift through, evaluate and consider applying. Unfortunately and quite commonly, time constraints and an inability to access these data sets leave many oncologists struggling to ensure that they’re aware of crucial practice-altering findings. This creates an almost insurmountable obstacle for clinicians in community practice because they are not only confronted almost overnight with thousands of new presentations and data sets to consider but they are also severely restricted in their ability to review and interrogate the raw findings.

To bridge the gap between research and patient care, this CME activity will deliver a serial review of the most important emerging data sets on targeted therapies for Hodgkin lymphoma from the latest ASH meeting, including expert perspectives on how these new evidence-based concepts may be applied to routine clinical care. This activity will assist medical oncologists, hematologists, hematology-oncology fellows and other healthcare professionals in the formulation of optimal clinical management strategies and the timely application of new research findings to best-practice patient care.

LEARNING OBJECTIVES

- Evaluate the benefits and risks of brentuximab vedotin after long-term follow-up of patients with relapsed or refractory Hodgkin lymphoma.
- Assess the efficacy and safety of brentuximab vedotin in investigational settings, such as for elderly and pediatric patients with Hodgkin lymphoma or as salvage therapy prior to stem cell transplant.
- Appraise recent clinical trial data on the use of panobinostat in combination with chemotherapy for relapsed or refractory Hodgkin lymphoma.
- Recall the clinical features, treatment, survival outcomes and prognosis of gray zone lymphoma.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains slides and edited commentary. To receive credit, the participant should review the slide presentations, read the commentary, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/5MJCASH2014/6/CME.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Andrew M Evens, DO, MSc
Professor of Medicine
Chief, Division of Hematology/Oncology
Tufts University School of Medicine
Leader, Lymphoma Program
Tufts Cancer Center
Boston, Massachusetts

Advisory Committee and Contracted Research: Celgene Corporation, Millennium: The Takeda Oncology Company, Seattle Genetics.

Christopher Flowers, MD, MS
Associate Professor of Hematology and Medical Oncology
Emory School of Medicine Winship Cancer Institute
Atlanta, Georgia

Advisory Committee: Biogen Idec, Genentech BioOncology, Roche Laboratories Inc; Consulting Agreements: Algeta ASA, Celgene Corporation, OptumRx Inc; Contracted Research: Abbott Laboratories, Celgene Corporation, Millennium: The Takeda Oncology Company, Spectrum Pharmaceuticals Inc.

Craig Moskowitz, MD
Clinical Director, Division of Hematologic Oncology
Attending Physician, Lymphoma and Adult BMT Services
Member, Memorial Sloan-Kettering Cancer Center
Professor of Medicine, Weill Medical College of Cornell University
New York, New York

Advisory Committee: GlaxoSmithKline, Roche Laboratories Inc, Seattle Genetics; Contracted Research: Cephalon Inc, GlaxoSmithKline, Roche Laboratories Inc, Seattle Genetics; Paid Research: Plexxikon Inc.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology/Biogen Idec, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc, Seattle Genetics and Spectrum Pharmaceuticals Inc.

Hardware/Software Requirements:
- A high-speed Internet connection
- A monitor set to 1280 x 1024 pixels or more
- Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
- Adobe Flash Player 10.2 plug-in or later
- Adobe Acrobat Reader
- (Optional) Sound card and speakers for audio

Last review date: March 2014
Expiration date: March 2015
To go directly to slides and commentary for this issue, [click here](https://example.com).

One of the best ways to allow experienced clinical investigators to illustrate their perspectives on the translation of research to clinical care is to ask them to present and discuss patients from their practices, and this month in Miami and New York we will do just that by hosting daylong CME symposia structured around 32 cases managed by 10 invited researchers ([Join us! Click here](https://example.com)). In reviewing the first faculty slide set submitted for the Miami meeting by Dr Craig Moskowitz, I was immediately drawn to his selection of a case of a 72-year-old woman with classical Hodgkin lymphoma (cHL) who had significant comorbidities requiring a plethora of medications. The dilemma of this important cHL subset — which is estimated to comprise up to 35% of cHL patients — is that the natural history of the disease seems somewhat more aggressive, yet poor health and reduced baseline renal function often mean that even modified chemotherapy regimens may not be delivered at close to full doses.

Dr Moskowitz includes in his talk a slide illustrating the design of a single-arm Phase II trial in older patients evaluating the antibody-drug conjugate brentuximab vedotin (bv) followed by scaled back chemotherapy (AVD [doxorubicin/vinblastine/dacarbazine]) and then bv consolidation. This is not the first time we have heard about this intriguing study, as last summer at our lymphoma think tank Dr Andrew Evens presented an 87-year-old woman who had entered the trial but unfortunately had major problems with the chemotherapy during the first cycle, including sepsis and congestive heart failure.

For precisely this reason many clinicians have for some time expressed great interest in taking things even further and eliminating chemotherapy altogether for the “frail elderly” population, and at ASH we got a first glimpse that this in fact may be quite possible. Specifically, preliminary data were presented from 11 of the projected 50 patients aged 60 and older enrolled on an ongoing Phase II study of bv up front. The results were impressive, as 7 patients achieved a complete response (CR) and 2 had a partial response. Among these, the 2 that got my attention were a 92-year-old woman with Stage IV disease and PS 1 and an 88-year-old man with Stage II disease and PS 2, both of whom had CRs. It is worth noting that the durability of these responses in this very early data set has not yet been established, and it could be, as is being tested in the trial discussed at the think tank, that integration of some form of chemotherapy will be optimal.
The challenge of the frail elderly patient permeates all corners of oncology, and oncologists frequently inquire about the potential up front role of agents like T-DM1 in HER2-positive breast cancer or ibrutinib in CLL and mantle-cell lymphoma as less toxic alternatives when even “gentle” forms of chemotherapy like paclitaxel and bendamustine pose a significant risk. I will be curious to find out in Miami what happened with Dr Moskowitz’s 72-year-old patient and to hear his thoughts and those of the other faculty members on how this compelling issue plays out in their practices as well as their perspectives on new HL data sets presented in New Orleans, including those profiled below:

- **More follow-up of bv in relapsed/refractory (RR) HL**

The **3-year update** from the pivotal Phase II study revealed a median overall survival of 40.5 months with 14 of the 76 patients who had objective responses still in remission, suggesting that a fraction of these patients may be cured. Perhaps even more impressive, the waterfall plot (see below) illustrates that all but 2 of the 98 patients experienced decreases in tumor size, and 34 patients (35%) achieved CR.

![Responses in a Phase II Trial of Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma](image)

- Patients received a median of 9 cycles (range, 1–16) of B-vedotin
- Those who achieved an objective response received more cycles of therapy

With permission from Gopal AK et al. *Proc ASH* 2013;Abstract 4382.

On the flip side of the coin, while bv is generally better tolerated than conventional chemotherapy, toxicities are a reality, and almost half of the patients in this study experienced some form of neuropathy (only 9% being Grade 3 or 4). In a related matter, an interesting ASH poster described **8 cases of pancreatitis** in patients receiving bv, including 2 who died of that complication. Although this rare but
concerning side effect has been reported with other tubulin drugs, it is of interest that CD30 is present on normal pancreatic cells, but it is not clear if this is of clinical significance with regard to this phenomenon. Regardless, many investigators caution that a baseline serum amylase and lipase should be obtained and that abdominal discomfort be investigated thoroughly.

In New Orleans we were also treated to a fascinating report from Memorial Sloan-Kettering on the use of bv prior to autotransplant. This Phase II study demonstrated that in 11 of 42 patients (26%), bv resulted in FDG PET-negative scans, allowing patients to proceed to transplant without more chemotherapy. This appealing strategy seems likely to be considered for nonprotocol therapy in the future. Finally, a Phase I/II study reported encouraging response and tolerability findings using bv in 16 pediatric patients with HL.

• Phase I study of panobinostat combined with ICE (ifosfamide/carboplatin/etoposide) in RR cHL

The subject of novel agents in HL was addressed at ASH in a brilliant review lecture by Dr. Anas Younes. In addition to other monoclonal antibodies and antibody-drug conjugates, he highlighted histone deacetylase inhibitors and agents targeting the PI3 kinase pathways as ones to look out for. In that regard, in New Orleans we saw data from a Phase I study evaluating panobinostat combined with ICE. The regimen resulted in CR in 15 of 21 (71%) patients, and all were able to have stem cells harvested successfully, with 17 responding patients going on to autotransplant without additional treatment except mobilization chemotherapy. Toxicity was considered “acceptable” and included fatigue, GI complaints and myelosuppression, but of course Phase III testing will be needed to determine the potential additional benefit of this regimen.

• Gray zone lymphoma case series

Dr. Evens and colleagues reported a retrospective analysis of 96 patients diagnosed with this difficult-to-classify B-cell lymphoma that commonly has features intermediate between primary mediastinal diffuse large B-cell lymphoma (DLBCL) and cHL. This important paper identified a subset of these patients who present without mediastinal involvement and have distinct characteristics. Patients in this series received various forms of chemotherapy and, in most cases, rituximab, and overall the outcomes seem less favorable than with either DLBCL or cHL. At a median follow-up of 25 months, 2-year progression-free survival is 41% and overall survival is 84%, suggesting that much more research is needed to optimize the care of these patients.

• Reduced-intensity conditioning for allotransplant for RR HL in the “bv era”

Allotransplant is thought to have the potential to eradicate HL via a graft-versus-host effect, and this retrospective report of 27 patients suggested better outcomes among patients who had received prior bv. The findings, while preliminary, appear to have renewed interest in allotransplant for HL.
Next, on the final issue of our ASH review series, we visit perhaps the most exciting corner of the field — chimeric antigen receptor T-cell therapy, as discussed by an investigator in the middle of it all, Dr David Porter.

Neil Love, MD
Research To Practice
Miami, Florida
Phase I Study of Panobinostat with ICE in Relapsed/Refractory Hodgkin Lymphoma

Presentation discussed in this issue


Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Christopher Flowers, MD, MS (2/24/14)
Background

- The standard approach for refractory or recurrent cHL is treatment with an effective salvage chemotherapy followed by stem cell transplantation.
- The commonly used regimen ICE produces complete response (CR) rates ranging from 26% (response evaluation by CT) to approximately 61% (with augmented ICE; response evaluation by PET) (Blood 2001;97:616; 2012;119:1665).
- Panobinostat, a potent oral pan-deacetylase inhibitor, has shown activity in relapsed/refractory cHL after transplant with an acceptable toxicity profile (JCO 2012;30:2197).
- **Study objective:** To evaluate the efficacy and safety of panobinostat in combination with ICE for relapsed/refractory cHL.

Oki Y et al. Proc ASH 2013;Abstract 252.

---

Phase I Study Design — Schedule A

<table>
<thead>
<tr>
<th>Week -1</th>
<th>Week 1</th>
<th>Week 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st cycle</td>
<td></td>
<td>Recovery</td>
</tr>
<tr>
<td>2nd cycle</td>
<td></td>
<td>Recovery</td>
</tr>
<tr>
<td>3rd cycle</td>
<td></td>
<td>Response evaluation</td>
</tr>
</tbody>
</table>

- **Panobinostat**
  - Three times a week (M/W/F)
  - Start 1 week prior to ICE
  - Initial dose 20 mg po (M/W/F)
  - Escalate to 30 mg po (M/W/F)

- **ICE**
  - Ifosfamide 5 g/m² on day 1
  - Carboplatin AUC 5 on day 1
  - Etoposide 100 mg/m² on days 1-3

Oki Y et al. Proc ASH 2013;Abstract 252.
Phase I Study Design — Schedule B

Week 1 → Week 1 → Week 2
1st cycle → Recovery
2nd cycle → Recovery
3rd cycle → Response evaluation

- **Panobinostat**
  - Three times a week (M/W/F)
  - Start 1 week prior to ICE
  - 30 mg po (M/W/F)

- **ICE**
  - Ifosfamide 5 g/m² on day 1
  - Carboplatin AUC 5 on day 1
  - Etoposide 100 mg/m² on days 1-3


Eligibility and Cohorts

- **Eligibility**: Relapsed/refractory CHL after front-line anthracycline-containing regimen
- **21 patients evaluable (25 patients treated)**
  - Primary refractory disease (n = 9)
- **Primary endpoint**: Determination of the recommended Phase II dose of panobinostat (maximum tolerated dose and different dosing schedules)
- **Secondary endpoints**: Toxicity, response rate
- **Cohort assignment**
  - Cohort 1 (schedule A): 20 mg, 12 doses (n = 6, dose-limiting toxicity [DLT] in 1)
  - Cohort 2 (schedule A): 30 mg, 12 doses (n = 3, no DLT)
  - Expansion cohort (schedule A): 30 mg, 12 doses (n = 10)
  - Expansion cohort (schedule B): 30 mg, 9 doses (n = 6, 4 patients under treatment not included in analysis)

Response

![Bar chart showing response rates: CR 71% and ORR 86% with n = 21.]

With permission from Oki Y et al. *Proc ASH* 2013;Abstract 252.

Subsequent Treatment

- 17 responding patients received autologous stem cell transplant without additional treatment except mobilization chemotherapy.
- 3 patients received one or more additional therapies followed by autologous stem cell transplant.
- All 20 patients had successful harvest and engraftment.

Adverse Events (N = 21)

- No Grade 3-4 nonhematologic toxicity
- Grade 4 thrombocytopenia: 84% (schedule A); 50% (schedule B)
- No deaths

With permission from Oki Y et al. Proc ASH 2013;Abstract 252.

Author Conclusions

- Panobinostat with ICE as a salvage treatment for cHL has acceptable toxicity and promising efficacy, with a CR rate of 71%.
- An alternative schedule (schedule B) is currently accruing patients.

Oki Y et al. Proc ASH 2013;Abstract 252.
Investigator Commentary: Phase I Study of Panobinostat with ICE in Relapsed/Refractory cHL

Panobinostat emerged around the same time as brentuximab vedotin as a promising agent for relapsed/refractory HL. Early evidence suggested activity of HDAC inhibitors, in particular panobinostat, in patients with HL. However, although brentuximab vedotin received FDA approval and is now incorporated into therapy for relapsed/refractory HL, panobinostat has not been approved.

This Phase I study employed a 3 + 3 design to identify the dose of panobinostat that could be used safely in combination with standard ICE chemotherapy as a salvage regimen for relapsed/refractory HL. With the combination, fatigue was a frequent side effect in 43% of patients, as reported in other studies with HDAC inhibitors.

(Continued)

Nausea and vomiting occurred in 43% and 29% of the patients, respectively. Some hematologic toxicities were also observed, as would be expected with the ICE regimen.

The overall response rate of 86% and complete response rate of 71% with panobinostat/ICE are higher than what might be anticipated with ICE therapy alone. However, further randomized studies comparing the combination to ICE alone as a salvage regimen are needed before definitive conclusions can be made.

Interview with Christopher Flowers, MD, MS, February 24, 2014